講演者
Filter by:
Scott Anseth, Orthopaedic Surgeon, Twin Cities Orthopedics
Dr. Anseth was born and raised in Montana. He attended Concordia College and the University of North Dakota School of Medicine. He completed an orthopedic surgery residency in Flint, MI and a fellowship in Adult Reconstruction in La Jolla, CA. Dr. Anseth joined Twin Cities Orthopedics in 2005. He currently leads the Total Joint Service Line. During his time with TCO, Dr. Anseth has helped develop joint replacement centers and bundled payment programs. As the Total Joint service line lead, he is part of the team evaluating new technologies in joint replacement to understand the benefits as well as the risk.
Spencer Bailey, VP Market Access & Reimbursement, SetPoint Medical
Mr. Bailey's 20-year career in the business of healthcare spans the provider, payer and medical device industries. His work in market access and reimbursement of medical devices has touched orthopedics, cardiac surgery, biologics and neuromodulation. His current role as VP Market Access at SetPoint Medical will establish reimbursement for the world's first neuroimmune modulation therapy to treat autoimmune conditions - the SetPoint System.
Joe Biller, Managing Partner, American Century Private Investments
Joe is a Managing Partner at 3x5 Partners, a venture capital firm that collaborates with passionate entrepreneurs who are developing solutions in response to global healthcare and climate needs. Previously, Joe was a Managing Director at SightLine Partners, where he helped raise $250M+ over 15 years to invest in the healthcare sector. During his tenure at Sightline, Joe served on numerous boards and completed transactions in over 50 companies with his partners. He began his career at Bremer Asset Management and is based in the Twin Cities.
Milo Bissin, Southwest & Central US Market Manager, Life Sciences and Healthcare, Silicon Valley Bank
No bio available.
Allen Burton, DVP and Chief Medical Officer, Abbott
Dr. Allen W. Burton is medical director of Abbott’s neuromodulation business, inclusive of Abbott’s neurostimulation and chronic pain management product portfolios. He is a board-certified anesthesiologist with an added certification in pain management and brings nearly 20 years of experience in patient care to Abbott, alongside a strong background leading large-scale clinical research programs. Dr. Burton joined Abbott in October 2015 and served as principal investigator for the ACCURATE and SUNBURST clinical trials. Prior to joining Abbott, he served as Chairman of the Department of Pain Medicine at the University of Texas MD Anderson Cancer Center from 2000-2011. From 2011-2015, Dr. Burton practiced privately with Houston Pain Associates, where he directed clinical research and participated in many clinical trials. Dr. Burton obtained his bachelor of science at the University of Notre Dame, medical doctorate at Baylor College of Medicine, and completed his residency at Brigham and Women’s Hospital, Harvard Medical School. He has published more than 50 peer-reviewed articles and authored two text books, taught and lectured nationally and internationally, and played an active leadership role among numerous pain societies and editorial boards.
Andy Danielsen, Chief Business Development Officer, Mayo Clinic Ventures
Andrew J. Danielsen serves as Chief Business Development Officer at Mayo Clinic, where he oversees the licensing, technology development, venture investment and business development functions. Collectively, these groups work to identify, develop and commercialize Mayo Clinic intellectual property. These activities generated over $100 million in revenue for Mayo Clinic in 2020. Prior to joining Mayo Clinic Ventures in 2002, Mr. Danielsen conducted research at Mayo Clinic where he worked to identify therapeutic targets in breast and ovarian cancer. Mr. Danielsen serves on several committees throughout Mayo Clinic, including the Executive Subcommittee of the Medical-Industry Relations Committee. He is also a member of multiple groups responsible for funding innovative new technologies or startup companies, including the Mayo Clinic Venture Fund Investment Committee, the Discovery Translation Program, and the Department of Business Development Investment Committee. Mr. Danielsen received his B.S. in biochemistry and molecular biology from the University of Wisconsin-Eau Claire and his M.S. in molecular biology from Mayo Clinic Graduate School of Biomedical Sciences.
Jolayne Devers, President and Partner, JD Lymon
With more than three decades of experience in reimbursement, Jo has held diverse positions across provider, medical device companies, and health plan organizations. In her role as a consultant, she focuses on expediting the adoption of innovative technologies by integrating coding and payment policy initiatives, including applications for HCPCS/CPT and ICD-10 coding. Additionally, she employs strategic advocacy tactics to influence the payer coverage landscape. Jo also serves as the CPT and RUC staff member for the American Society of General Surgeons.
Mark Domyahn, Partner, JD Lymon Grp
Mark has dedicated over 25 years of his career to the healthcare industry, primarily concentrating on medical technology, provider reimbursement, and health economics. He possesses extensive expertise in payment policy, particularly regarding new technologies, including CMS's New Technology Add-On Payment, Transitional Pass-Through, and New Technology APC programs. Mark has led reimbursement initiatives for multinational corporations as well as startups, and as a consultant, he has assisted numerous clients in developing and implementing effective reimbursement strategies.
Mark DuVal, CEO, DuVal & Associates
Mark DuVal, JD, FRAPS, is CEO of DuVal & Associates, P.A., a law firm dedicated to counseling companies in the medical device, pharmaceutical, biotech, food, and nutritional supplement industries.
His practice includes providing strategic regulatory advice, developing compliance programs, designing, and implementing sophisticated marketing programs, counseling on reimbursement matters, conducting sales training and interfacing extensively on behalf of companies with the FDA with relation to product approvals and clearances, clinical trial negotiations, approvals, policy arguments, appeals, etc.
Prior to founding the firm, Mark was general counsel for 3M Pharmaceuticals and Drug Delivery Systems working both domestically and internationally. He was on assignment for 3M Health Care Systems, Ltd. In Europe based out of the United Kingdom. He then worked at Medtronic in Corporate Compliance for FDA, Anti-kickback, False Claims Act, HIPAA & HITECH, and other advice related to the FDA-regulated industry.
Mark earned his Juris Doctor from the William Mitchell College of Law where he served as executive editor on the law review, and his Bachelor of Arts in Public Administration from St. Cloud State University. Mark has served on various boards including the Minnesota BioBusiness Alliance, Minnesota Biosciences Council, The Food and Drug Law Institute and has been a former Chairman of the Minnesota State Food, Drug, and Medical Device Section of the Minnesota State Bar Association. He is also on the Board of Advisors of the Masters in Regulatory Affairs Services program at St. Cloud State University.
Mark is a frequent national speaker and writer on issues relating to product approvals/clearances; combination products, product advertising and promotion, Antikickback, and False Claims Act (reimbursement) matters.
James Eadie, MD, Managing Director, Sante Ventures
James joined Santé Ventures in 2009 and is an emergency medicine physician. Prior to joining Santé, James served in the Air Force and was Vice-Chair of Emergency Medicine at Wilford Hall Medical Center, an academic level-one trauma center. He completed two tours in Iraq as a Critical Care Transport Team Chief and Emergency Department Commander, before separating honorably as a Major in 2008. James is an Oversight Committee member for the University of Michigan’s Michigan Translational Research & Commercialization program, an early-stage granting body for life science companies. He is also a Mentor in the Coulter Program at Michigan and a Board Member of the Michigan Center for Integrative Research in Critical Care. James is board-certified in emergency medicine and completed his residency at Massachusetts General Hospital and Brigham and Women’s Hospital. He earned his MD from the Harvard-MIT Program in Health Sciences and Technology (HST), his MBA from the University of Texas McCombs School of Business and his BS in bioengineering from the University of Michigan.
Morgan Evans, Founder & CEO, Agitated Solutions
Morgan Evans is an engineer by training, an entrepreneur by nature, and an executive by necessity. With nearly two decades’ experience in the full lifecycle of MedTech product development and delivery - from idea through regulatory approval to commercialization - she works from first-hand knowledge of how to conceive and design technically complex and highly regulated products, attract talent and build teams, and establish sustainable companies. The throughline in Morgan’s MedTech career is an iterative style of problem-solving that focuses one eye on the immediate task, and the other eye on how a process can be improved. Needing technical expertise for her own product development, Morgan built a network of collaborators that continues to work together through AVIO Medtech Consulting. Finding high age and gender hurdles to her early effort to raise funds, she found partners with whom to form Engage Venture Partners to open doors to angel and early series investors for entrepreneurs, and to make direct investments using special purpose investment vehicles that provide flexibility and collaborative due diligence. She remains a hands-on leader in an innovative medical device company - Agitated Solutions, Inc (ASI). ASI’s initial product received its first regulatory clearance in early 2024. ASI has a portfolio of new products in the development and regulatory pipeline. Morgan is involved in a variety of organizations and forums exploring MedTech development, women’s business leadership, and entrepreneurial activity. As a nearly lifelong basketball player and coach, Morgan volunteers with school teams in her home community, as well as with AAU summer programs. But that’s just for the sheer joy of it.
Bryan Feldhaus, President, DuVal & Associates
Bryan serves as President of DuVal & Associates. He specializes in advising medical device, pharmaceutical and nutritional supplement companies on FDA legal, regulatory and compliance matters. His practice includes providing legal/regulatory advice for the design and implementation of sophisticated marketing and compliance programs under the Food, Drug & Cosmetic Act, the Anti-Kickback Statute, the False Claims Act, the Eliminating Kickbacks in Recovery Act, the Physician Payments Sunshine Act, and HIPAA. Bryan also advocates on behalf of clients with the FDA and the Office of Inspector General relating to medical product submissions and appeals, promotional activities, inspections, and enforcement matters. Additionally, Bryan counsels companies on compliance and regulatory due diligence matters, conducts compliance and due diligence assessments, and provides national compliance trainings to help clients satisfy their regulatory obligations and achieve their business objectives. Finally, Bryan advises medtech companies regarding their HIPAA and GDP obligations as it relates to patient privacy, clinical trials, and medical device development. Prior to joining DuVal & Associates, Bryan enjoyed a fourteen-year career as a shareholder at a Minneapolis law firm. As a former trial attorney, Bryan is experienced in trial and appellate matters, including complex commercial and business disputes, intellectual property litigation, including patent and trademark litigation, and counseled clients on regulatory, compliance and business ethics matters. Bryan is a 2006 graduate from the University of St. Thomas School of Law. He obtained an LL.M. degree in Corporate Compliance and Organizational Ethics from the University of St. Thomas School of Law in 2015 and obtained a Cybersecurity and Privacy Law Certificate from Mitchell Hamline School of Law in 2019.
Virginia L. Giddings, PhD, Vice President, Exploration, Edwards Lifesciences
Virginia is Vice President of Exploration at Edwards Lifesciences, where she builds external partnerships globally to advance breakthrough innovation. She has a track record of delivering innovation to patients, with roles spanning medical device, pharmaceutical and nutrition businesses. Virginia has focused on advancing innovation, with R&D, Program Management, and Business Development leadership roles at Stryker, Abbott, and Johnson & Johnson. She chairs the Cornell Biomedical Engineering Advisory Council, is an AIMBE Fellow, and is a co-founder of MedtechWomen. She holds B.S. and M.Eng. degrees in Mechanical Engineering from Cornell and a Ph.D. in Mechanical Engineering from Stanford.
Kate Hobbs, Equity Research Analyst, Vice President, T. Rowe Price
Experienced investor with two decades of fundamental equity investing experience and a track record of outperformance in the healthcare, energy, and consumer sectors on long-only and long/short platforms. Areas of expertise include medical device, life science tools, diagnostics, and healthcare services. Passionate about impact and transforming healthcare delivery.
Drew Hykes, CEO, Inari Medical
Drew is a proven medical device operating executive with broad functional, geographic and sector experience. Drew served as CEO of Inari Medical from 2023 until its acquisition by Stryker Corporation in 2025 for $5 billion. From 2020-2022, Drew was Chief Operating Officer of Inari Medical leading its day to day business operations. From 2017-2019 he served as Inari’s Chief Commercial Officer. Prior to Inari, from 2012-2016 Drew served as the VP of Commercial Operations at Sequent Medical where he led the commercialization strategy for the WEB Aneurysm Embolization system from early prototype to broad adoption in the European market. Sequent was acquired by Terumo Corporation in July 2016 for $380 million. Prior to Sequent, Drew spent 11 years at Medtronic. His roles at Medtronic included the VP of Marketing for the AF Solutions business, VP of Clinical and Regulatory for the AF Solutions business and Director of Investor Relations. Drew also spent three years on an expatriate assignment in Europe leading the launch of Medtronic’s first drug eluting coronary stent. Prior to Medtronic, he spent four years at ABN AMRO bank in Chicago focused on healthcare transactions. He holds a B.B.A. in Finance from the University of Wisconsin and an MBA from Harvard Business School.
Frank Jaskulke, Vice President, Sales & Business Development, Avio Medtech
With nearly two decades at Medical Alley Association, he served in various leadership roles, most recently as Vice President of Innovation and Head of Medical Alley Starts. Frank has been instrumental in advancing the medtech sector, connecting companies with partners, investors, and key talent. He has a proven track record in international business development and strategic services, particularly for startup companies. Frank holds a Master of Political Leadership from the University of Minnesota Duluth and a Bachelor of Arts in Political Science from the University of Minnesota. He is known for his dedication to fostering innovation and his deep connections within the medtech community.
Justin Klein, MD, JD, Co-Founder & Managing Partner, Vensana Capital
Justin Klein, MD, JD, is a co-founder and Managing Partner at Vensana Capital, a venture capital & growth equity investment firm dedicated to partnering with entrepreneurs who seek to transform healthcare with breakthrough innovations in medical technology. Justin was previously a partner at NEA, one of the largest and most active venture capital firms in the world. Justin also worked at the Duke University Health System where his experience included roles in strategy, finance and operations as Duke built one of the nation’s first integrated healthcare delivery systems. Justin currently or previously served on the board of directors of Cartiva (acquired), ChromaCode, CV Ingenuity (acquired), Epix Therapeutics (acquired), FIRE1, Intact Vascular, Metavention, Personal Genome Diagnostics, PhaseBio Pharmaceuticals (IPO), Relievant MedSystems, Senseonics (IPO), Topera (acquired), Ulthera (acquired), VertiFlex, Vesper Medical, and VytronUS. Justin graduated with an AB in Economics, a BS in Biological Anthropology & Anatomy, and a Minor in Chemistry from Duke University. He also concurrently earned his MD from the Duke University School of Medicine and his JD from Harvard Law School.
Saravana Kumar, CEO, 4C Medical Technologies
It is hard to innovate, harder to show it works first and then works consistently, hardest to find the right people to work with to make it happen. Everything is worth it when you see someone's life change as a result. Changing lives one person at a time - this is my passion.
David Lewis, Managing Partner, Gilmartin Capital
David has 25 years of healthcare experience evaluating Medical Device, Life Science Tool, Diagnostic and Digital Health companies and advising boards on strategic and financial direction. Prior to founding Gilmartin Capital, David was a Managing Director at Morgan Stanley and Head of Morgan Stanley’s medical technology equity research practice for the last 15-years. He was a top ranked analyst at Morgan Stanley and in the Institutional Investor (II) Medical Supplies & Devices annual poll. Before joining Morgan Stanley, David was a partner and top ranked medical technology analyst at Thomas Weisel Partners and a founding member of the healthcare practice. David received a BA in healthcare policy with honors from the University of Pennsylvania. David serves as an advisor to Equalize Health, a non-profit that is developing medical devices for underserved populations. He lives outside of San Francisco with his wife Lynn, daughter Olivia, son Jack, and dog Tucker. David is a struggling guitar player, recovering a cappella singer, and he loves the mountains in any season.
Chris Lyle, VP Evidence Strategy, Evidence Strategy, DuVal & Associates
Chris focuses his consulting practice on the intersection of clinical evidence, regulatory requirements, and payer coverage policies to support product approval requirements and demonstrate value to payers and providers. A biostatistician by training, Chris has successfully negotiated study designs with FDA and several OUS regulatory agencies. Chris has over 25 years of experience in the medical device industry and has supported the development of medical devices, biologics, and pharmaceuticals. Prior to joining DuVal & Associates, Chris was a Partner at the JD Lymon Group, a Minneapolis-based reimbursement and market access consulting firm, where he focused on evidence development initiatives to support positive coverage arguments. He spent the prior 12 years at RCRI, a Minneapolis-based device CRO, where he held various executive positions including roles overseeing corporate operations, biostatistics, and market access. Before that Chris was a biostatistician at 3M Company working with 3M Pharmaceuticals and multiple medical device divisions. Chris holds a B.A. in Mathematics from St. Olaf College, and an M.S. in Applied Statistics from Florida State University. He speaks routinely on evidence strategies and clinical study design to support pre- and post-approval requirements and has served on the community faculty of both Metropolitan State University and the St. Cloud State University Masters of Regulatory Affairs program. He is also a co-founder and Board member of JDL Access, LLC, a prior authorization and patient appeals firm based in Minneapolis.
Srijoy Mahapatra, MD, Divisional Vice President, Abbott Ventures
My mission is to help people live longer and feel better focused on arrhythmias (Atrial Fibrillation). I'm seeking to amplify that impact by adding artificial intelligence (AI) to my skill set. My tools are innovation blending engineering, medicine, and business insights that I gained through diverse experiences and education. Since college, I have strived to learn about cardiac electrophysiology in the broadest sense-medicine, clinical trials, regulatory pathways, engineering, and the business. I started as an electrical engineer working on a wireless EKG at MIT. Seeing how it helped patients inspired me to go to medical school and become a cardiac electrophysiologist. I’m licensed to practice medicine in Minnesota, Washington DC, Virginia, Ohio, and California. After training at Mayo, I worked in an academic practice for 6 years. I started-up 2 companies and then spent 9 years in the medical device industry. While my passion is electrophysiology, I have worked in multiple areas of cardiology. I have been credited with 14 patents in the space, which generates $2B in revenue and touches 500K patients a year. I am unapologetic about challenging accepted wisdom. An example includes disproving that lesions have to be transmural to get isolation around the pulmonary veins. This insight led to the understanding of High Power Short Duration Ablation, which became a core organizational competitive differentiator for St. Jude. I am a constant learner and every year try to learn a new skill (piano and golf are examples). Because I have found the greatest innovation comes from the intersection of fields, I have sought new work experiences in adjacent fields to medical device. Most recently, I was the Chief Strategy Officer at a state-wide $6B hospital system. This helped me better understand the challenges hospitals face and how they make decisions. It also exposed me to diverse fields like neurology and cell therapy, which could potentially help in arrhythmia care. During my 2-years as a hospital administrator, I realized that arrhythmia care could vary depending on which doctor you saw. Much of therapy is heuristic and image based. At the same time, I was learning more about AI and thought AI would be a great way to equalize care of arrhythmias. At Neutrace, we seek to give every arrhythmia patient world-class care.
Michael Mahoney, Chairman & CEO, Boston Scientific Corp.
Michael “Mike” Mahoney is Chief Executive Officer of Boston Scientific Corporation and Chairman of the company’s Board of Directors. Boston Scientific is a global medical technology leader with approximately $12.7 billion in annual revenue and commercial representation in more than 130 countries. Under Mike’s leadership, Boston Scientific is delivering on its mission to transform lives through innovative medical solutions that improve the health of patients around the world. The company’s team of more than 45,000 global employees reaches over 33 million patients each year, providing a range of technologies and solutions that span cardiovascular interventions, structural heart, electrophysiology, endoscopy, neuromodulation and urology, and women’s health. Since joining Boston Scientific, Mike has focused the company on addressing the needs of the evolving healthcare landscape by driving improvements to patient outcomes and increasing healthcare economic efficiency and access. Under his leadership, Boston Scientific has brought many transformational medical devices to market while creating significant value to its shareholders. Mike’s career spans more than 25 years of success building market-leading medical device, capital equipment and healthcare IT businesses. Prior to Boston Scientific, he served as Worldwide Chairman of the Medical Devices and Diagnostics (MD&D) division of Johnson & Johnson. Prior to joining Johnson & Johnson, Mike was President and Chief Executive Officer of Global Healthcare Exchange (GHX). For the first 12 years of his career, Mike advanced through a series of leadership roles at General Electric Medical Systems, including General Manager of the company’s Healthcare Information Technology business. Mike serves on the Board of Directors of Baxter International, the Board of Boys & Girls Club of Boston and as the chair of the Board of Governors of Boston College CEO Club. He earned his B.B.A. in Finance from University of Iowa and his M.B.A. from Wake Forest University. He is married and has three children.
Steven Manoukian, MD, Senior Vice President, HCA Healthcare; Service Lines & Clinical Resiliency, HCA Healthcare
Steven V. Manoukian, MD, FAHA, FACC, FSCAI is Senior Vice President, HCA Healthcare, Nashville, TN. Dr. Manoukian was recruited in 2008 and leads Service Lines & Clinical Resiliency for HCA enterprise-wide, one of the largest healthcare systems, across its over 180 US and UK facilities. Service Lines provide focused expertise, comprehensive strategic skills, leadership and collaboration, which inform clinical, business and operational decision-making. Clinical Resiliency is at the intersection of clinical quality, costs and value achieved for patients and other stakeholders. Other HCA responsibilities include the Senior Leadership, Operating and Research Institute Steering Committees. Prior HCA roles include: Vice President in the Clinical Services Group, Medical Director of Cardiovascular Services, Director of Cardiovascular Research and practicing interventional cardiologist at Centennial Heart, all in Nashville, Tennessee. Before joining HCA, Dr. Manoukian spent 19 years at Emory University School of Medicine in Atlanta, including fellowships in Cardiology and Interventional Cardiology and 15 years on the faculty, including as Director of Interventional Cardiology at Emory University Hospital-Midtown. His residency and chief residency were at the State University of New York at Stony Brook and he is a graduate of New York University School of Medicine. Dr. Manoukian received his undergraduate degree from St. John’s University in New York. Dr. Manoukian is an experienced academician and clinical researcher, with numerous leadership roles and publications who lectures at national society, clinical and research meetings. His awards include the Emory Excellence in Teaching Award and American Federation for Clinical Research Trainee Investigator Award. He is a Subject Matter Expert for the FDA’s Total Product Life Cycle Advisory Program (TAP). Dr. Manoukian was selected as the American Heart Association (AHA) 2024 Healthcare Volunteer of the Year. He is the primary architect of the joint AHA, HCA Healthcare and HCA Healthcare Foundation’s Getting to the Heart of Stroke initiative, which is enhancing collaboration between neurology and cardiology providers, improving diagnosis of stroke etiology and outcomes, while reducing stroke recurrence. Dr. Manoukian serves or has served in numerous capacities with national organizations, including the American College of Cardiology (ACC) NCDR ACTION Registry Steering Committee; Society of Thoracic Surgeons (STS)/ACC TVT Registry Stakeholder Advisory Group; AHA Quality Accreditation Science Committee and Advocacy Coordinating Committee; Society for Cardiovascular Angiography & Interventions (SCAI) Development & Industry Relations Committee and Finance Committee; Heart Valve Collaboratory Leadership and the Extracorporeal Life Support Organization (ELSO) Strategic Advisory Council. He is a board observer for viz.ai and VitalConnect. Dr. Manoukian was a Medical Reporter for FOX television in Atlanta from 1998-2008.
Juan-Pablo Mas, Partner, Action Potential VC
Juan-Pablo Mas is a Partner at Action Potential VC, a bioelectronic medicine fund founded by GlaxoSmithKline, and is based in Santa Cruz, CA. He represents APVC on the Boards of Cala Health, Exo Imaging, Neuspera Medical, Presidio Medical, Saluda Medical, SetPoint Medical, Onc.AI and previously CVRx. Prior to APVC, he was an investor at Lightstone Ventures and Morgenthaler Ventures, where he was a Board observer at Ardian, Twelve, Nuvaira, Cabochon, and Miramar Labs. Prior to investing, Juan-Pablo led R&D and Strategy teams in Medtronic’s CardioVascular Division and was a member of the Global Brand Strategy team at Eli Lilly. Juan-Pablo earned an MBA from the Stanford Graduate School of Business as a Bonini Fellow, an MS in Electrical Engineering from Stanford University, and a BS in EE from the University of Massachusetts. He now serves on the Oversight Committee for Stanford’s Wu Tsai Neuroscience Institute, the Advisory Board for UCSF’s Rosenman Institute, the DEI Advisory Committee for RockHealth.org, and is a co-founder of the non-profit LatinxVC which is dedicated to increasing diversity within venture capital. Juan-Pablo is originally from Puerto Rico and played Division I men’s lacrosse at UMass.
Cherly Matter, Head of Customer Success, Avenda Health
Cheryl Matter, PhD, is the Head of Customer Success at Avenda Health, the developer of Unfold AI, a clinically validated, FDA-cleared prostate cancer mapping and decision support platform that recently received a CPT code and associated payment. In her current role, she drives market adoption by working closely with clinical sites to ensure seamless integration, positive experience and stakeholder value. For the past 20 years, Matter advanced innovative technologies across academic, corporate, payer, and provider environments, integrating user and payer perspectives into product development to improve outcomes and reduce costs. Her previous leadership roles include positions at BCBS MN, Livio Health, LifeSpark Health, and Careforth. Dr. Matter holds a PhD in Molecular and Medical Pharmacology from UCLA.
J Mocco, Physician, Mount Sinai Health System
Dr. Mocco earned his medical degree from Columbia University College of Physicians and Surgeons. During his residency in Neurological Surgery at the Neurological Institute of New York, he also obtained a Master of Science in Biostatistics from Columbia's Mailman School of Public Health. He went on to complete a fellowship in Endovascular Neurosurgery at the University of Buffalo under the tutelage of Dr. Nick Hopkins. Throughout his career, Dr. Mocco has been dedicated to advancing cerebrovascular care through high-quality clinical research and technological innovation. Dr. Mocco has served as a key advisor or Board member for 11 med-tech start ups that have achieved successful exit (acquisition or IPO). He has helped three companies achieve valuations in excess of $1B. He has served as the national or international Principal Investigator (PI) or Co-PI for numerous multicenter prospective trials, including COMPASS (RCT), THERAPY (RCT), PHIL, POSITIVE (RCT), FEAT (RCT), COAST, ACCESS, AMERICA, LARGE, COMFORT, EVERRUN, Barrel, INVEST, and TNK (RCT). Currently, he is a BOD member/observer for Synchron, Imperative Care, Endostream, Kandu, and Protembis and serves as Multi-Principal Investigator (MPI) for the NIH/NINDS StrokeNet Thrombectomy Endovascular Platform (STEP) and Contact-PI for the NIH/NINDS StrokeNet New York City Collaborative Regional Coordinating Center. As Director of the Cerebrovascular Center at Mount Sinai, he oversees ischemic and hemorrhagic stroke care across a network of nine New York Region hospitals.
Carla Monacelli, Partner, Exec, JD Lymon Grp
Carla brings over 30 years of experience in Government Affairs and Market Access. She has provided executive leadership in reimbursement functions for both global companies and startups, including LivaNova, Nevro, AqueSys, and Torax Medical. Her distinctive expertise lies in developing and assembling teams to overcome market access barriers associated with complex therapies. With an entrepreneurial mindset, Carla co-founded JD Lymon Group, as well as JDL Access and Argenta Advisors.
Kieran Murphy, Vice President, Global Market Access and Reimbursement, Shockwave Medical
Shockwave Medical - Vice President, Global Market Access & Reimbursement
Jeff Peters, Venture Partner, Healthcare, OrbiMed Advisors LLC
Jeff joined OrbiMed as a Venture Partner in 2018 and currently serves as the Founder and Chief Executive Officer of evanesce Medical. Jeff has over 25 years of medical device experience with executive and strategic roles in companies including Cardialen, ev3 (now Medtronic), Anulex, and Boston Scientific; and financial investment and analysis roles at Black River Asset Management, Foundation Medical, and Dain Rauscher Wessels. Jeff received his B.S. and M.B.A. from the University of Minnesota.
Stacey Pugh, CEO, Endogenex
Stacey Pugh is the Chief Commercial Officer at Butterfly Network. As a leader in Medical Technology, she has more than 20 years of experience in medical device research, development and commercialization. Stacey joined Butterfly in 2021 and will lead the company in the planning, organization, and implementation of all sales and marketing activities. Prior to Butterfly, Stacey was President of Medtronic’s Neurovascular Operating Unit, where she provided overall global strategic leadership, guided marketing and business development and was responsible for revenue growth. Prior to this role, Stacey was Vice President and General Manager of Neurovascular & Cerebral Spinal Fluid (CSF) businesses and was responsible for leading the company’s European, Middle Eastern and African (EMEA) business programs and developing trade strategies to support the global revenue and market share growth of Medtronic Neurovascular products. In addition, Stacey held various leadership roles in Covidien’s Neurovascular division as Vice President of Global Medical Affairs where she provided strategic direction for all medical affairs activities and executed strategic market access plans. As a registered nurse, Stacey spent the early years of her career in research, critical care and trauma nursing, and nursing education.
Karen Ruszkoski, Vice President, Market Access and Reimbursement, Volta
Karen Ruszkoski is a seasoned medical device professional with two decades of experience in market access, health economics, marketing, and reimbursement. Karen is currently the Vice President of Market Access and Reimbursement at Volta Medical. Throughout her career, she has worked with leading organizations including Boston Scientific, St. Jude Medical, and Abbott. Karen is a passionate advocate for public health, specifically ensuring all patients have access to innovative technologies. She is skilled at developing evidence generation plans to support value propositions for various stakeholders, including governments, payers, hospital administrators, and physicians. Karen has also successfully influenced reimbursement decisions, including coding, coverage, and payment, for new technologies. Karen holds a B.S. in health management and policy from the University of New Hampshire. She also has a master’s in public health from the University of Michigan. Additionally, she is a certified professional medical coder from the American Academy of Professional Coders.
Kathy Sherwood, Senior Vice President Global Market Access, Inspire Medical Systems Inc.
Broad cross-functional background with deep expertise in Global Market Access and Marketing. Detailed knowledge of global reimbursement and pricing. Strong analytical and planning skills, combined with the ability to coordinate the efforts of many to meet organizational goals. - Over 25 years management & leadership - 12 years Reimbursement & Pricing - 4 years Business Development (M&A) - 3 years defibrillator & pacemaker Sales - 17 years Product Development & Operations background - Highly analytical Marketing & Business Strategy roles
Amrinder Singh, Partner, Vensana Capital
Amrinder Singh is a Partner at Vensana Capital and joined the firm in 2021. Amrinder has nearly two decades of medtech operating and investing experience, ranging from engineering, corporate strategy, and venture capital investing. Prior to Vensana Capital, Amrinder was a Senior Investment Director at Medtronic Ventures where he supported new investments in the medtech and digital health spaces, providing operational and board management support to portfolio companies. Prior to his investment career, Amrinder led Business Development & Strategy for Medtronic’s care management services, helping to shape the vision for Medtronic's value-based healthcare strategy. Amrinder started his career at Medtronic within the Corporate Strategy group. Before joining Medtronic, Amrinder held product management and engineering positions at Thoratec Corporation. Amrinder graduated from University of California, Davis in Biosystems Engineering and earned his MBA from Northwestern University, Kellogg School of Management.
Lisa Wipperman-Heine, Board Director and Medtech Executive
Lisa Wipperman Heine currently serves on the Board of Directors for several public, private equity, and early-stage, VC-backed medtech/biotech companies. In addition, she has held executive leadership roles in both large medtech companies as well as venture-backed start-ups. Most recently, Lisa was President and Chief Executive Officer at preCARDIA, Inc., an early-stage, heart failure-focused medtech company which was acquired by Abiomed, Inc., in 2021. Ms. Heine also previously served in multiple leadership roles at ev3 and Covidien, Inc., including Global Vice President of Medical Affairs for Vascular Therapies. During her tenure at Covidien, she helped drive the strategy in support of a $1.7B business and was also responsible for leading the strategy and operations of Clinical Affairs, Healthcare Economics, Policy and Reimbursement, and Medical Education functions. Lisa’s current roles include serving as an independent director for Surmodics, Inc. (NASDAQ: SRDX), Miromatrix (NASDAQ: MIRO) and Gradient Denervation Technologies. She also previously served on the board of Natus Medical (NASDAQ: NTUS) which was acquired by the Archimed Group in 2022.
Sarah Worrell, CEO, Melodi Health
Sarah is the founder and CEO of Melodi Health, a women’s health focused medical device company partnered with Medtronic to address profound unmet needs for women experiencing breast cancer and related surgical complications. Prior to Melodi, Sarah was a consultant to large multi-national companies helping to develop their R&D pipelines through immersive ethnographic and preclinical research. She began her career in medical device product development at Guidant in 2003 after receiving her degree in Chemical Engineering and Polymer Science from the University of Minnesota and has experienced all aspects of product development throughout her career from concept generation to post-market monitoring. She is passionate about applying her technical degree to practical health issues, particularly in women’s health.
Jennie N. Xue, Senior Managing Director, Guggenheim Partners
Jennie Xue is a Senior Managing Director on the Healthcare team at Guggenheim Securities where she focuses on M&A advisory, specializing in the medical device space and also digital devices. She was previously at BofA Merrill and Merrill Lynch, with +16 years of experience advising on sellside / buyside M&A and public / private financings for both start-up entrepreneurs as well as multinational strategics. Jennie graduated from the Jerome T. Fisher Program at the University of Pennsylvania with dual degrees from the Wharton School and the School of Engineering.
Darshana Zaveri, Founder & Managing Partner, Catalyst Health Ventures
Darshana is a Founder and Managing Partner of Catalyst Health Ventures (CHV). She is actively involved in all aspects of fund management including investments and capital raising and has led several investments in the medical device, women’s health and diagnostics markets. She led CHV’s investments in Augmenix (acquired by Boston Scientific), nVision Medical (acquired by Boston Scientific), Maxwell Health (acquired by SunLife), Aria CV, PanTher Therapeutics, AtaCor Medical, Instylla, Avive and Rejoni. She currently (or previously) represents CHV on the Boards of all companies. Prior to joining CHV in 2007, Darshana was an Investigator at Vertex Pharmaceuticals, and an integral part of drug development programs in oncology, metabolic disease, and immunology. Previously she worked at Genome Therapeutics, a Massachusetts-based biotechnology company and at the Dana Farber Cancer Institute and completed an internship at the United Nations. She has authored several publications and scientific journal articles. Darshana currently serves as an advisor of the Deshpande Center for Technological Innovation at MIT, (a foundation that helps MIT students and faculty commercialize breakthrough technologies and inventions), as a Board Director of The New England Venture Capital Association (NEVCA) and as a lead advisor to the Portfolia FemTech fund (an investment fund designed for women). Darshana received an M.P.A. from Harvard University, an M.A. in Cell and Molecular Biology from Boston University, and a B.S. in Biochemistry from Bombay University in Bombay, India.